MedTrace Logo

Seroprevalence of Hepatitis E in People With an Organ Transplant

NCT02190253 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 447

Last updated 2026-05-04

No results posted yet for this study

Summary

Background:

\- The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant. They found that hepatitis E may not go away by itself in these people. It becomes chronic. This can cause serious liver disease. More than half the people who had organ transplant who had hepatitis E seemed to get a chronic infection.

Researchers want to find out if hepatitis E happens this often in patients who have liver, kidney, or small bowel transplants in the United States. If it does, they want to know why. They want to know if chronic hepatitis E will become an important medical problem. This research might help improve care for people who have a transplant. It also might help researchers prevent the spread of hepatitis E.

Objective:

\- To see how many patients who have received or are waiting for certain transplants have antibodies to hepatitis E virus.

Eligibility:

\- Adults over age 18 who have had a liver, kidney, liver and kidney, or small bowel transplant, or are on a waiting list for one.

Design:

* Participants will be enrolled from 3 transplant centers.
* Participants will complete a questionnaire. They will be asked about possible risk factors for hepatitis E exposure.
* Participants will have a blood sample drawn through a needle placed in a vein.

Conditions

  • Hepatitis E

Sponsors & Collaborators

  • Georgetown University

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • University of Wisconsin, Madison

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Marc G Ghany, M.D. · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-12
Primary Completion
2019-02-05
Completion
2019-02-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02190253 on ClinicalTrials.gov